Drugs / Osemitamab
Osemitamab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05608785 | Jan → Dec 2023 | gastric cancer, gastroesophageal cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04495296 | Aug 2020 → Jun 2026 overdue | cancer of unknown primary site | Suzhou Transcenta Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04396821 | May 2020 → May 2026 overdue | cancer of unknown primary site, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Suzhou Transcenta Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05190575 | Jan 2022 → May 2023 | biliary tract neoplasm | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06093425 Comparator | Jun 2026 → Oct 2029 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Suzhou Transcenta Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osemitamab | “Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma” NCT06093425 ↗ |
| Known as | MSB-018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095388 ↗ |
| Known as | TST001 | “Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma” NCT06093425 ↗ |
| Modality | Monoclonal antibody | “TST001 is a humanized IgG1 monoclonal antibody.” NCT04396821 ↗ |
| Route | Intravenous | “Dosed every 2 weeks IV with TST001” NCT04396821 ↗ |